{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:36:58Z","timestamp":1756895818899},"reference-count":10,"publisher":"Wiley","issue":"9-10","license":[{"start":{"date-parts":[[2004,10,22]],"date-time":"2004-10-22T00:00:00Z","timestamp":1098403200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The antifungal susceptibility of isolates from Chinese dermatomycosis patients to amorolfine was investigated following National Committee for Clinical Laboratory Standards (NCCLS) protocols. In total, 383 isolates were tested, including 132 strains from tinea pedis, 148 strains from tinea corporis\/cruris, and 103 strains from onychomycosis. The minimum inhibitory concentration (MIC) of amorolfine against dermatophytes ranged from 0.01 to 0.08\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>. The MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> of amorolfine for <jats:italic>Trichophyton rubrum<\/jats:italic> were both equal to 0.04\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>; for <jats:italic>T. mentagrophytes<\/jats:italic> these MICs were 0.04\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> and 0.08\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> respectively; and for <jats:italic>Epidermophyton floccosum<\/jats:italic> they were 0.02\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> and 0.04\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> respectively. The MIC range of amorolfine against <jats:italic>Candida parapsilosis<\/jats:italic> was 0.5\u201316\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>. MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> for <jats:italic>C. parapsilosis<\/jats:italic> were 0.5 and 2\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>. MIC ranges of amorolfine against <jats:italic>Scopulariopsis<\/jats:italic> spp. and <jats:italic>Acremonium<\/jats:italic> spp. were 0.5\u20134 and 2\u20138\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>, respectively. <jats:italic>Candida albicans<\/jats:italic>, <jats:italic>Fusarium solani<\/jats:italic> and <jats:italic>Aspergillus flavus<\/jats:italic> required relatively higher concentrations of amorolfine to inhibit their growth (MIC 0.125\u201364\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>, MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> were 4 and 64\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>). The results demonstrated that amorolfine is the only topical agent that has such a potent antifungal activity and a broad spectrum against a wide range of pathogenic fungi.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2004.01014.x","type":"journal-article","created":{"date-parts":[[2004,10,22]],"date-time":"2004-10-22T10:18:16Z","timestamp":1098440296000},"page":"402-406","source":"Crossref","is-referenced-by-count":12,"title":["<i>In vitro<\/i> susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China"],"prefix":"10.1111","volume":"47","author":[{"given":"R.\u2010Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.\u2010P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2010N.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2010Y.","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.\u2010D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.\u2010Q.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,22]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00270.x"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.1.341-344.2000"},{"key":"e_1_2_14_4_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. NCCLS Document M27\u2010A","author":"National Committee for Clinical Laboratory Standards","year":"1997"},{"key":"e_1_2_14_5_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility of Conidium\u2010forming Filamentous Fungi. Proposed Standard M38\u2010P","author":"National Committee for Clinical Laboratory Standards","year":"1998"},{"key":"e_1_2_14_6_2","first-page":"860","article-title":"A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong","volume":"115","author":"Cheng S","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_14_7_2","first-page":"26","article-title":"Analysis of 766 isolates from onychomycosis patients","volume":"32","author":"Wang AP","year":"1995","journal-title":"Chin J Dermatol"},{"key":"e_1_2_14_8_2","first-page":"993","article-title":"In vitro antifungal activity of amorolfine, a new morpholine antimycotic agent","volume":"44","author":"Hiratani T","year":"1991","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_14_9_2","first-page":"1007","article-title":"In vitro antifungal activities of amorolfine against fresh isolates from patients with cutaneous mycosis","volume":"44","author":"Uchida K","year":"1991","journal-title":"Jpn J Antibiot"},{"issue":"60","key":"e_1_2_14_10_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2133.2001.00047.x","article-title":"The rationale for combination therapy","volume":"145","author":"Evans EG.","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_14_11_2","first-page":"S235","article-title":"Combination testing of antifungals against yeast and dermatophytes","volume":"16","author":"Harman S","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2004.01014.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2004.01014.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:11:45Z","timestamp":1693505505000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2004.01014.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":10,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1439-0507.2004.01014.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2004.01014.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}